GlassScriptPhysician profile
Scot D Hines
NPI 1447352034
$7,689.06
in general payments reported to CMS, 2019-2025
33 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,554 · 2020: $152 · 2021: $368 · 2022: $389 · 2023: $1,075 · 2024: $960 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,269.34 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic USA, INC. | $1,172.96 | 2019 | |
| Abbvie INC. | $616.11 | 2021-2025 | |
| Neurelis, INC. | $416.41 | 2023-2025 | Valtoco |
| Sk Life Science, INC. | $390.39 | 2021-2025 | Xcopri |
| Tg Therapeutics, INC. | $333.22 | 2024-2025 | |
| Neuropace, INC. | $274.50 | 2019-2025 | |
| Eisai INC. | $242.17 | 2024-2025 | |
| Biogen, INC. | $229.05 | 2023-2025 | Tysabri, Vumerity, Tysabri |
| Ucb, INC. | $200.29 | 2020-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $196.02 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $162.86 | 2023-2025 | Nuplazid, Daybue |
| Medtronic, INC. | $138.47 | 2023 | Accurian |
| Greenwich Biosciences, INC. | $133.28 | 2019 | |
| Sunovion Pharmaceuticals INC. | $123.10 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.78 | 2023-2025 | |
| Argenx US, INC. | $93.53 | 2022 | |
| Depuy Synthes Sales INC. | $77.44 | 2020 | |
| Alexion Pharmaceuticals, INC. | $74.43 | 2021-2022 | |
| Celgene Corporation | $59.56 | 2022-2023 | Zeposia |
| Merz Pharmaceuticals, LLC | $53.63 | 2023-2024 | Xeomin |
| Nevro Corp. | $50.01 | 2023-2024 | Senza |
| Allergan, INC. | $42.98 | 2020 | |
| Zimmer Biomet Holdings, INC. | $36.23 | 2022 | |
| Lundbeck LLC | $34.78 | 2019-2022 | |
| Monteris Medical Corporation | $34.06 | 2022 | |
| Si-Bone, INC. | $25.58 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $25.06 | 2023 | Ingrezza, Ongentys |
| Merz North America, INC. | $18.64 | 2019 | |
| Radius Health, INC. | $18.00 | 2022 | |
| Gt Medical Technologies, INC | $16.93 | 2023 | Gammatile |
| Ipsen Biopharmaceuticals, INC | $16.70 | 2023 | Dysport |
| Avanos Medical | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.